Advances in cell sources of hepatocytes for bioartificial liver

查看全文 作　　者：Xiao-Ping Pan , Lan-Juan Li State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

出　　处：《Hepatobiliary & Pancreatic Diseases International》索引2012年第11卷第6期,共12页

基　　金：supported by grants from the Chinese High-Tech Research & Development (863) Program (2011AA020104);Science Fund for Creative Research Groups of the National Natural Science Foundation of China (81121002);the Fundamental Research Funds for the Central Universities;the Technology Group Project for Infectious Disease Control of Zhejiang Province (2009R50041) 摘　　要：BACKGROUND: Orthotopic liver transplantation (OLT) is the most effective therapy for liver failure. However, OLT is severely limited by the shortage of liver donors. Bioartificial liver (BAL) shows great potential as an alternative therapy for liver failure In recent years, progress has been made in BAL regarding genetically engineered cell lines, immortalized human hepatocytes, methods for preserving the phenotype of primary human hepatocytes, and other functional hepatocytes derived from stem cells. DATA SOURCES: A systematic search of PubMed and ISI Web of Science was performed to identify relevant studies in English language literature using the Key words such as liver failure bioartificial liver, hepatocyte, stem cells, differentiation, and immortalization. More than 200 articles related to the cell sources of hepatocyte in BAL were systematically reviewed. RESULTS: Methods for preserving the phenotype of primary human hepatocytes have been successfully developed. Many genetically engineered cell lines and immortalized human hepatocytes have also been established. Among these cell lines the incorporation of BAL with GS-HepG2 cells or alginate encapsulated HepG2 cells could prolong the survival time and improve pathophysiological parameters in an animal model of liver failure. The cBAL111 cells were evaluated using the AMC-BAL bioreactor, which could eliminate ammonia and lidocaine, and produce albumin. Importantly, BAL loading with HepLi-4 cells could significantly improve the blood biochemical parameters, and prolong the survival time in pigs with liver failure. Other functional hepatocytes differentiated from stem cells, such as human liver progenitor cells, have been successfully achieved. CONCLUSIONS: Aside from genetically modified liver cell lines and immortalized human hepatocytes, other functionalhepatocytes derived from stem cells show great potential as cell sources for BAL. BAL with safe and effective liver cells may be achieved for clinical liver failure in the near future. 关键词：bioartificial LIVER LIVER failure HEPATOCYTE LIVER CELL source stem CELL DIFFERENTIATION IMMORTALIZATION

相关文献

参考文献（185）
引证文献（7）
耦合文献（141）

参考文献(185)

引证文献(7)

耦合文献(141)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Advances in cell sources of hepatocytes for bioartificial liver

参考文献(185)

引证文献(7)

耦合文献(141)

用户提示